Exelixis
EXEL
#1704
Rank
ยฃ7.75 B
Marketcap
ยฃ27.16
Share price
0.62%
Change (1 day)
43.93%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : ยฃ0.15 Billion

According to Exelixis's latest financial reports the company's total debt is ยฃ0.15 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ0.14 B-5.15%
2022-12-31ยฃ0.15 B313.84%
2021-12-31ยฃ37.98 M5.48%
2020-12-31ยฃ36.01 M-1.64%
2019-12-31ยฃ36.61 M211.58%
2018-12-31ยฃ11.75 M6.31%
2017-12-31ยฃ11.05 M-92.79%
2016-12-31ยฃ0.15 B-45.65%
2015-12-31ยฃ0.28 B23%
2014-12-31ยฃ0.22 B8.92%
2013-12-31ยฃ0.21 B1.34%
2012-12-31ยฃ0.20 B77.87%
2011-12-31ยฃ0.11 B-13.52%
2010-12-31ยฃ0.13 B174.46%
2009-12-31ยฃ49.2 M-38.72%
2008-12-31ยฃ80.29 M31.27%
2007-12-31ยฃ61.16 M-1.52%
2006-12-31ยฃ62.1 M-28.05%
2005-12-31ยฃ86.31 M12.46%
2004-12-31ยฃ76.75 M23.6%
2003-12-31ยฃ62.09 M34.68%
2002-12-31ยฃ46.11 M36.6%
2001-12-31ยฃ33.75 M237%
2000-12-31ยฃ10.01 M21.69%
1999-12-31ยฃ8.23 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
ยฃ17.15 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ20.32 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ30.43 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ41.02 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ48.21 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ28.53 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ53.17 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ2.6 M-98.32%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ30.87 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA